Publicaciones en las que colabora con Ruth Vera García (18)

2024

  1. PD-1/LAG-3 co-signaling profiling uncovers CBL ubiquitin ligases as key immunotherapy targets

    EMBO Molecular Medicine, Vol. 16, Núm. 8, pp. 1791-1816

2023

  1. Plasma fractalkine contributes to systemic myeloid diversity and PD-L1/PD-1 blockade in lung cancer

    EMBO Reports, Vol. 24, Núm. 8

2022

  1. Circulating Low Density Neutrophils Are Associated with Resistance to First Line Anti-PD1/PDL1 Immunotherapy in Non-Small Cell Lung Cancer

    Cancers, Vol. 14, Núm. 16

  2. Clinical landscape of LAG-3-targeted therapy

    Immuno-Oncology and Technology, Vol. 14

  3. The multi-specific VH-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activity

    British Journal of Cancer, Vol. 126, Núm. 8, pp. 1168-1177

2021

  1. Understanding lag-3 signaling

    International Journal of Molecular Sciences, Vol. 22, Núm. 10

2020

  1. ESMO Clinical Research Observatory (ECRO): improving the efficiency of clinical research through rationalisation of bureaucracy

    ESMO Open, Vol. 5, Núm. 3

  2. PD-L1 in systemic immunity: Unraveling its contribution to PD-1/PD-L1 blockade immunotherapy

    International Journal of Molecular Sciences, Vol. 21, Núm. 16, pp. 1-17

  3. Systemic blood immune cell populations as biomarkers for the outcome of immune checkpoint inhibitor therapies

    International Journal of Molecular Sciences, Vol. 21, Núm. 7

2019

  1. Functional systemic CD4 immunity is required for clinical responses to PD-L1/PD-1 blockade therapy

    EMBO Molecular Medicine, Vol. 11, Núm. 7

  2. PD-L1 expression in systemic immune cell populations as a potential predictive biomarker of responses to PD-L1/PD-1 blockade therapy in lung cancer

    International Journal of Molecular Sciences, Vol. 20, Núm. 7

2018

  1. A randomized phase II clinical trial of dendritic cell vaccination following complete resection of colon cancer liver metastasis 11 Medical and Health Sciences 1112 Oncology and Carcinogenesis

    Journal for ImmunoTherapy of Cancer, Vol. 6, Núm. 1

  2. Effect of Primary Tumor Side on Survival Outcomes in Untreated Patients With Metastatic Colorectal Cancer When Selective Internal Radiation Therapy Is Added to Chemotherapy: Combined Analysis of Two Randomized Controlled Studies

    Clinical Colorectal Cancer, Vol. 17, Núm. 4, pp. e617-e629

2017

  1. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials

    The Lancet Oncology, Vol. 18, Núm. 9, pp. 1159-1171

  2. PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity

    Cell Reports, Vol. 20, Núm. 8, pp. 1818-1829

2016

  1. Pancreatic neuroendocrine tumors: Challenges in an underestimated disease

    Critical Reviews in Oncology/Hematology, Vol. 101, pp. 193-206

2014

  1. Selective Internal Radiation Therapy (SIRT) with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as first-line treatment of non-resectable liver metastases from colorectal cancer: The SIRFLOX study

    BMC Cancer, Vol. 14, Núm. 1

1996

  1. Analisis comparativo entre m-BACOD, COP-BLAM I, MACOP-B y CHOP en el tratamiento de los linfomas de mediano y alto grado de malignidad

    Revista del Instituto Nacional de Cancerologia, Vol. 42, Núm. 2, pp. 73-81